Suven Life Sciences Update

Edit this post
1. One of the readers had asked about Suven Life Sciences and this below information can be of use for the readers and the same is listed in below paragraphs.

2. Suven Life Sciences has received its first product patent from the US Patent Office. The granted claims of the patent include the class of selective Serotonin receptor affinity compounds discovered by Suven and being developed as therapeutic agents. According to the invention patent disclosure, the compounds are useful in the treatment of neuro-degenarative disorders like Alzheimer's, Parkinson, Schizophrenia and Huntington.Suven has filed 29 product patent applications through PCT covering more than 145 countries.

3. The company has filed its first investigational new drug application with DCGI to conduct clinical study on their developmental candidate SUVN-502 and several candidates are in discovery pipeline undergoing GLP pre-clinical studies.

4. Suven Life Science is pleased by the issuance of this patent by US Patent office for our drug candidates that are being developed for CNS disorders which targets $18 billion potential market opportunity, said Venkat Jasti, CEO of Suven.

Nifty / Bank Nifty Option Tip

Looking to trade intraday Nifty or Bank Nifty options? Our Nifty / Bank Nifty Option Tip shares trading calls with a defined entry, target and stop loss, so you know your risk before you trade. It suits traders who follow the market on a trading screen as well as those who place orders through their broker or by phone. Click on Image or Post Title to Read More.

Latest Video Reviews by Clients

Watch video reviews recorded by our clients about their experience with Indian-Share-Tips.com services, including the Nifty / Bank Nifty Option Tip and Delivery Tip. Click on Image or Post Title to Read More.

Awards and Recognition

See the awards and recognition Indian-Share-Tips.com has received over the years for its work in stock market research and investor education. Click on Image or Post Title to Read More.